biotech


Skye Bioscience Completes Drug Production for Phase 1 Clinical Study

September 20th, 2022 - Ryan Allway

San Diego, California, Sept. 20, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) that it has completed the production of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) for Skye’s Phase 1 clinical […]

Delta 9 Completes Private Placement of Common Share

September 9th, 2022 - Ryan Allway

WINNIPEG, Manitoba, Sept. 09, 2022 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company“), announces that it has completed a private placement of 1,650,000 common shares of the Company (“Common Shares”), for a deemed price of $0.1250 per Common Share, to various subscribers (the “Offering”).   A number […]

BioHarvest Sciences Inc. Launches First Major United States Marketing Campaign

August 18th, 2022 - Ryan Allway

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – August 18, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”) has announced the first multimedia campaign for VINIA™ in the USA, Phase 1. The company is scaling up its US marketing in line with a 2022 growth plan that aims for significant […]

BioHarvest Sciences Inc. Commences Trading on the OTCQB Market

July 18th, 2022 - Ryan Allway

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – July 18, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”) “) is pleased to announce that its common shares are now trading on the OTCQB® Venture Market under the ticker symbol “CNVCF”.   “Admission to the OTCQB® market is an important step […]

Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program – Ketamine-Assisted Therapy for Alcohol Use Disorder

July 5th, 2022 - Ryan Allway

Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III   Toronto, Ontario–(Newsfile Corp. – July 5, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a revenue-generating biotechnology company researching, developing and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder […]

BioHarvest Sciences Inc. Reports Strong Q2 2022 Results with Major Achievements on All Fronts

July 5th, 2022 - Ryan Allway

VINIA® sales orders reached a record high of USD 947k representing 99% growth compared to Q2 2021 and 24% growth compared to Q1 2022 BioHarvest reiterates guidance for year-on-year sales orders growth of 2.5-3.5X to reach USD 5M – 7M Started production of VINIA® at new 20 tons/year facility enabling the scaling of VINIA® sales […]

22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO

June 16th, 2022 - Ryan Allway

CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century Group Integration of GVB Biopharma Proceeding at a Rapid Pace   BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, […]

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders

May 11th, 2022 - Ryan Allway

The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments   NAPLES, FL, May 11, 2022 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced plans to transfer and spin-off its cannabinoid clinical development pipeline […]

TRYP Therapeutics Doses First Patient In Phase II Psilocybin-Assisted Therapy Clinical Trial

April 27th, 2022 - Ryan Allway

Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder San Diego, California — (April 27, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that the […]

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

April 11th, 2022 - Ryan Allway

PharmAla’s GMP MDMA will accelerate trial work funded by Australia’s premier Psychedelics charity PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for Mind Medicine Australia. Mind Medicine Australia’s order will be available for delivery later this year, for use in an ethics approved healthy persons trial and will be subject […]

Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer

March 28th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “Agreement”) dated March 24, 2022 with Praesidio Health Inc. (“Praesidio”). Pursuant to […]

Can-Fite Reports 2021 Financial Results & Provides Clinical Update

March 24th, 2022 - Ryan Allway

Cash balance of $18.9 million as of December 31, 2021 Signed out-licensing deal worth $42.7 million with Ewopharma Phase III psoriasis topline data expected Q2 2022 Namodenoson induced complete response and cleared all cancer lesions in advanced liver cancer patient in Can-Fite’s Phase II study Phase IIb NASH study is currently enrolling patients Pivotal Phase III […]

Eco Innovation Group Receives Notice of Allowance from USPTO Covering Glytech, LLC Supercritical Plant Extraction Technology

March 17th, 2022 - Ryan Allway

VAN NUYS, Calif., March 17, 2022 /PRNewswire/ — Eco Innovation Group, Inc. (OTC: ECOX) (“ECOX” or the “Company”), an innovative company aggregating investments in new technologies that promote environmental and social well-being and the advancement of green energy solutions, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office […]

Nova Mentis Announces Closing of Non-Brokered Financing

March 15th, 2022 - Ryan Allway

VANCOUVER, BC, March 15, 2022 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has completed a non-brokered private placement financing for total gross proceeds of $1,483,500 (the “Placement”).   The Company has issued 29,670,000 units […]

Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

March 14th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101. […]

Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering

February 22nd, 2022 - Ryan Allway

STONY BROOK, N.Y., February 22, 2022–(BUSINESS WIRE)–Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock (or common stock equivalents) at […]

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001

January 18th, 2022 - Ryan Allway

VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has obtained positive results from an in vivo oral bioavailability […]

FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada

January 18th, 2022 - Ryan Allway

TORONTO, January 18, 2022–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, warmly congratulates Eleanor N. Fish, Ph.D., a member of its Research and Clinical Advisory Board, on her appointment to the Order of […]

Doseology Appoints Maryam Marissen as CEO to Prepare for Next Growth Stage

January 13th, 2022 - Ryan Allway

VERNON, BC, Jan. 13, 2022 /CNW/ – Doseology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”) announces the appointment of Maryam Marissen as Chief Executive Officer and Director, effective immediately. Outgoing interim CEO and co-founder Daniel Vice will remain involved with the Company as an independent director. Doseology is a British Columbia-based, diversified life sciences company developing mushroom-based health and wellness solutions.   Doseology […]

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

January 4th, 2022 - Ryan Allway

– Last subject completed study in late 2021 with topline results expected in early 2022 –   – Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal –   NEW YORK, Jan. 4, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived […]

FSD Pharma Announces Share Repurchase Program

December 30th, 2021 - Ryan Allway

TORONTO, December 30, 2021–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that its Board of Directors has authorized the repurchase by the Company of up to 2,000,000 of its Subordinate Class […]

Entheon Biomedical Announces EEG Patent Application & Provides Research Update

December 16th, 2021 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – December 16, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its patent portfolio as […]

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai’s supply chain

December 9th, 2021 - Ryan Allway

TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health.   This new platform company will focus on the generation of intellectual property and further strengthen atai’s drug development pipeline of psychedelic and non-psychedelic compounds.   TryptageniX will also develop scalable and environmentally friendly […]

Pharmala Biotech Announces Hiring of Harpreet Kaur as Vice President of Research

November 2nd, 2021 - Ryan Allway

Dr. Kaur to accelerate PharmAla’s pre-IND program Toronto, Canada – PharmAla Biotech today announced the hiring of Dr. Harpreet Kaur as its new Vice President of Research, responsible for completion of the Company’s Pre-IND research into its novel formulations of MDMA. PharmAla has developed a novel formulation of MDMA, with a focus on reducing the […]

22nd Century Group to Begin Trading on Nasdaq on August 16, 2021

August 5th, 2021 - Ryan Allway

BUFFALO, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, announced today that its common stock has been approved for uplisting to the Nasdaq Capital Market effective as of the market open on August 16, 2021. […]

Bionomics Announces Plans to Conduct U.S. Initial Public Offering

August 2nd, 2021 - Ryan Allway

ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United States and a concurrent listing of ADSs on Nasdaq. The number of ADSs and price […]

Clearmind Medicine Inc. Announces Increase to Previously Announced Non-Brokered Private Placement

June 20th, 2021 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – June 20, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that, further to its press release of May 27, 2021, it intends to increase […]

Newly Public RYAH Medtech Sets Table for Expansion

May 13th, 2021 - Robin Lefferts

  RYAH Group, Inc. (CSE: RYAH) and its wholly owned subsidiary RYAH Medtech Inc. began trading publicly May 10, 2021 on the Canadian Securities Exchange. The reverse takeover was nearly two years in the making, bringing RYAH’s suite of smart cannabis and plant-based medicine devices (and the accompanying treasure trove of data) to the public […]

Core One Labs Completes Milestone Acquisition of Akome Biotech

May 4th, 2021 - Ryan Allway

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has completed the acquisition (the “Transaction”) of Akome Biotech Ltd. […]

Revive Takes a Step Closer to Launching New Psychedelic Delivery Mechanism

April 30th, 2021 - Ryan Allway

  Mental illness is the leading cause of disability in developed countries. In fact, half of Americans will experience mental illness in their lifetime and $350 billion is spent each year on treating depression in the U.S. and Europe alone. Psychedelics have emerged as a breakthrough treatment for many mental health disorders with fast-acting results, […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading